We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen ␣1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. These results together with the well-documented role of extracellular matrix (ECM) components and matrix degrading enzymes in formation of new blood vessels led us to investigate the effect of halofuginone on the angiogenic process. In a variety of experimental system, representing sequential events in the angiogenic cascade, halofuginone treatment resulted in profound inhibitory effect. Among these are the abrogation of endothelial cell MMP-2 expression and basement membrane invasion, capillary tube formation, and vascular sprouting, as well as deposition of subendothelial ECM. The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. or in the diet. The ability of halofuginone to interfere with key events in neovascularization, together with its oral bioavailability and safe use as an anti-parasitic agent, make it a promising drug for further evaluation in the treatment of a wide range of diseases associated with pathological angiogenesis.-Elkin, M., Miao, H.-Q., Nagler, A., Aingorn, E., Reich, R., Hemo, I., Dou, H.-L., Pines, M., Vlodavsky, I. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression, FASEB J. 14, 2477-2485 (2000)
Angiogenesis represents a multistep cellular process in which new vessels emerge from existing endothelial vasculature. The functional activity of a wide variety of molecules including growth factors, integrins, extracellular matrix (ECM) proteins, and proteolytic enzymes is required at different stages of angiogenesis. With the single exception of the reproductive cycle in women, angiogenesis in the adult is initiated only in response to pathological conditions, such as inflammation or hypoxia (1) (2) (3) . Moreover, angiogenesis is clearly implicated in tumor growth and metastasis (4, 5) . Expansion of microscopic solid tumor beyond ϳ1-2 mm in size requires continuous recruitment of new blood vessels. These vessels also serve as a gateway for cancer cells to enter the blood circulation and spread to distant organs. Developing new approaches to interfere with molecular and cellular events in the angiogenic process is therefore regarded as a highly effective means in the treatment of cancer and a wide range of human disorders, including rheumatoid arthritis, psoriasis, and diabetic retinopathy (3, 4, 6 -8) .
Regardless of the initiating event, the angiogenic stimulus results in local proliferation of endothelial cells, followed by degradation of the subendothelial capillary basement membrane (BM) and formation of vascular sprouts (2) . One of the rate-limiting steps in this process is the activity of matrix metalloproteinases (MMPs) in degrading structural ECM proteins. Endothelial cells were shown to produce a variety of MMPs (9) ; of these, MMP-2 is the most studied for its role in angiogenesis (2, 10, 11) . MMP-2 (72 kDa collagenase type IV) cleaves primarily type IV collagen (12) , the protein backbone of the endothelial basement membrane (13) . The advancing front of the migrating column of endothelial cells (vascular sprout) uses MMP-2 enzymatic activity to migrate through the basement membrane and ECM.
Different ECM components are thought to be implicated in vascular tube formation. It was proposed that type I collagen is involved in directing the migration and assembly of endothelial cells into the newly formed blood vessels (14, 15) . This hypothesis was supported by the observation that exogenous type I collagen promoted rapid tube formation by cultured confluent human dermal microvascular endothelial cells (16) . The tubes contained collagen fibrils in the lumen space, suggesting that the endothelial cells use the fibrils to fold and align into tube structures (16) . After a vascular tube has been formed, a new basement membrane is eventually deposited by the endothelial cells, a lumen is developed; finally, blood flow is established in the newly vascularized region (1, 2, 17) . The tight association of endothelial cells with the underlying BM plays an important role in the maintenance of their quiescence and differentiated phenotype (18 -20) .
In previous studies, we have demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid (495 Da, structure presented in the Merck Index) isolated from the plant Dichroa Febrifuga and used as a coccidiostat in chickens and turkeys (21) , suppresses MMP-2 (22) and collagen type ␣1 (I) (23) (24) (25) gene expression. A strong inhibitory effect of halofuginone on MMP-2 gene transcription activity was observed in human and murine bladder carcinoma cell lines (22) . Specific inhibition of collagen type I expression was demonstrated in a broad range of cell types of chicken, mouse, rat, and human origin, both in vitro and in experimental animals (21, (23) (24) (25) (26) . Moreover, exposure to halofuginone inhibited deposition of ECM by vascular smooth muscle (25) and kidney mesangial (27) cells.
In the present study, we investigated the effect of halofuginone on angiogenesis in different in vitro and in vivo experimental models. Halofuginone was found to exert a moderate anti-proliferative effect on vascular endothelial cells. A more pronounced inhibitory effect was noted on MMP-2 activity, resulting in a marked decrease in reconstituted BM (Matrigel) invasion by endothelial cells, capillary tube formation on ECM substrata, and aortic sprouting. In addition, halofuginone was found to inhibit deposition of BM-like ECM by cultured endothelial cells. Taken together, halofuginone appears to inhibit several essential stages of the angiogenic process, namely, endothelial cell proliferation, MMP-2 expression, and BM invasion as well as capillary tube formation and ECM deposition by the newly formed vessels. The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo by showing a marked inhibition of bFGF-induced neovascularization by systemic treatment with halofuginone, administered either intraperitoneally (i.p.) or in the diet, using the mouse corneal micropocket model.
MATERIALS AND METHODS
Dulbecco's modified Eagle's medium (DMEM), calf serum, penicillin, streptomycin, and saline containing 0.05% trypsin, 0.01 M sodium phosphate (pH 7.4), and 0.02% EDTA (trypsin/EDTA) were obtained from Biological Industries (BeitHaemek, Israel). Recombinant human bFGF was kindly provided by Dr. Peter Bohlen (Lederle Laboratories, Pearl River, N.Y. 
Cells
Clonal populations of bovine aortic endothelial cells (BAEC) were established and cultured in DMEM (1 g glucose/l) supplemented with 10% calf serum, as described (28) . Cells were cultured at 37°C in a 10% CO 2 humidified incubator and the experiments were performed with early (5-10) cell passages. Recombinant human bFGF (1 ng/ml) was added every other day during the phase of active cell growth.
Cell proliferation
Cell proliferation was evaluated by measuring [ 3 H]-thymidine incorporation. BAEC were plated (4ϫ10 4 cells/16 mm well/ ml) in DMEM (1 g glucose/l) supplemented with 10% CS. Four days after plating, the subconfluent cells were exposed to increasing concentrations of halofuginone (25-400 ng/ ml) in the presence of 1 ng/ml bFGF.
3 H-thymidine (1 Ci/well) was then added and DNA synthesis was assayed 48 h later by measuring the radioactivity incorporated into trichloroacetic acid (TCA) insoluble material (29) .
MMP-2 gelatinolytic activity
Subconfluent BAEC cell cultures were incubated for 24 h in the absence or presence of increasing concentrations (10 -100 ng/ml) of halofuginone in serum-free DMEM, and aliquots of the resultant conditioned medium were analyzed for collagenolytic activity. Collagenase activity was determined on gelatin impregnated (1 mg/ml, Difco, Detroit, Mich.) sodium dodecyl sulfate (SDS) 8% polyacrylamide gels, as described previously (10, 22) . Briefly, samples of the culture media, normalized for equal cell protein, were separated on the substrate-impregnated gels under nonreducing conditions, followed by 30 min incubation in 2.5% Triton X-100 (BDH, England). The gels were then incubated for 16 h at 37°C in 50 mM Tris, 0.2 M NaCl, 5 mM CaCl 2, 0.02% Brij 35 (w/v) at pH 7.6. At the end of the incubation period, the gels were stained with 0.5% Coomassie G 250 (Bio-Rad, Richmond, Calif.) in methanol/acetic acid/H 2 O (30:10:60).
Matrigel invasion assay
Blind well chemotaxis chambers with filters 13 mm in diameter were used. Polyvinyl pyrrolidine-free polycarbonate filters with pores 8 mm in size (Costar Scientific, Cambridge, Mass.) were coated with basement membrane Matrigel (25 g/filter) as described (30) . Cells (2ϫ10 5 ) suspended in DMEM containing 0.1% bovine serum albumin were added to the upper chamber in the absence or presence of increas-ing concentrations (1-50 ng/ml) of halofuginone. Medium conditioned by 3T3 fibroblasts was applied as a chemoattractant and placed in the lower compartment of the Boyden chamber (30) . Cells were assayed at 37°C in 5% CO 2 for 6 h. More than 90% of the cells attached to the filter after a 2 h incubation period. At the end of the incubation, the cells on the upper surface of the filter were removed by wiping with a cotton swab and cells on the lower surface of the filter were stained with Diff-Quick kit. Cells in different areas of the lower surface were counted and each assay was performed in triplicate. For chemotaxis studies, filters were coated with collagen type IV alone (5 g/filter) to promote cell adhesion. This amount of collagen does not form a barrier to the migrating cells but rather an attachment substratum (30) .
Organization of BAEC on a basement membrane substratum in vitro
Twenty-four-well plates were coated with 320 l of reconstituted basement membrane Matrigel (10 mg/ml) per well, which was allowed to polymerize for 30 min at 37°C. DMEM (500 l) was added into each culture well. BAEC suspended in 500 l of culture medium were then added to each well to a final concentration of 4 ϫ 10 4 cells per 1 ml. Halofuginone was added to some of the wells at various concentrations ranging from 10 to 200 ng/ml, and the plates were incubated for 18 h at 37°C. After removal of the medium by aspiration, the culture was fixed and capillary-like structures were visualized by phase microscopy and photographed (10) .
In vitro angiogenesis: rat aortic ring assay
SIS gel (31-33) was prepared according to the manufacturer's instructions. Briefly, 4 ml of chilled SIS gel solution were mixed with 0.6 ml 10ϫ phosphate buffered saline; 0.3 ml of ice-cold 0.5 N NaOH was then added. This solution was brought to pH 7.4 with 0.04 N HCl, aliquoted into 24-well plates (0.2 ml/well), and gelled at 37°C for 30 min. Thoracic aortas were obtained from 2-month-old Sprague-Dawley rats. The fibroadipose tissue was carefully removed under a dissecting microscope; aortic rings were sectioned (1 mm long) and placed on top of 0.2 ml SIS gel in 16 mm culture wells. SIS gel mixture (0.4 ml) was carefully poured on top of the ring. After the gel was formed, 0.4 ml of serum-free endothelial growth medium (Gibco BRL, Grand Island, N.Y.) was added and replaced every other day by fresh medium containing the increasing concentrations of halofuginone (25-500 ng/ml). Microvessel outgrowth was visualized by phase microscopy and photographed.
ECM deposition by cultured endothelial cells
For preparation of sulfate-labeled ECM, BAEC were seeded into 24-well plates at a confluent density (2.5ϫ10 5 cells/well), within 4 -6 h forming a growth-arrested cell layer. Under these conditions, the cells remained viable and retained their normal monolayer configuration and morphological appearance up to a concentration of 2 g/ml halofuginone. Na 2 35 SO 4 (40 Ci/ml) and increasing concentrations of halofuginone (10 -200 ng/ml) were added 1 and 3 days after seeding and the cultures were incubated without a change of medium. Nine days after seeding the ECM was exposed by dissolving (5 min, room temperature) the cell layer with phosphate-buffered saline (PBS) containing 0.5% Triton X-100 and 20 mM NH 4 OH, followed by four washes with PBS (25, 27) . The ECM was then digested with collagenase (3 U/ml, 18 h, 37°C), followed by trypsin (25 g/ml, 24 h, 37°C), and the solubilized material was counted in a ␤-counter.
In vivo angiogenesis: mouse corneal micropocket assay
A corneal micropocket was created in C57BL/6 mice (7-9 wk of age). A sucralfate and Hydron pellet containing bFGF was implanted into each pocket. Briefly, pellets were made of the slow-release polymer Hydron (polyhydroxyethylmethacrylate [polyHEMA] (Interferon Sciences, New Brunswick, N.J.) (10 l of 12% Hydron in ethanol), containing sucralfate (10 mg) and/or bFGF (10 g), as described (34) . The suspension was then embedded onto a sterilized nylon mesh (TETKO, 3-300/50, approximate pore size 0.4ϫ0.4 mm) and allowed to dry for 30 min. Subsequently, the fibers of the mesh were pulled apart and ϳ30 -40 uniformly sized pellets containing 80 -100 ng bFGF per pellet were collected. C57Bl/6 mice were anesthetized, the eye globe was proposed, and a lamellar micropocket was dissected toward the temporal limbus as described (34) . A single pellet was then introduced into the pocket. Halofuginone was administered either in the food (5 mg/kg) or by i.p. injections (2 g/mouse, once a day). On postoperative days 3 and 7, corneas were examined by slit lamp biomicroscopy and photographed to determine the neovascular response. The area (mm 2 ) of angiogenesis was calculated, using the formula of an ellipse, by measuring the maximal vessel length and the contiguous circumferential zone of neovascularization.
RESULTS

Inhibition of vascular endothelial cells proliferation by halofuginone
Angiogenesis involves local proliferation of vascular endothelial cells. We investigated the ability of halofuginone to inhibit the proliferation of actively growing BAEC. Subconfluent BAEC maintained for 4 days in medium containing 10% CS and 1 ng/ml bFGF were exposed (48 h, 37°C) to 3 H-thymidine in the absence and presence of increasing concentrations (25-400 ng/ml) of halofuginone. Low concentrations of halofuginone (Ͻ100 ng/ml) failed to exert an antiproliferative effect on vascular endothelial cells. Forty percent inhibition of 3 H-thymidine incorporation was observed at 100 ng/ml halofuginone, whereas ϳ80% inhibition was obtained at 400 ng/ml (Fig. 1) .
Effect of halofuginone on MMP-2 gelatinolytic activity expressed by vascular endothelial cells
We investigated the effect of halofuginone on MMP-2 activity expressed by BAEC. For this purpose, subconfluent cultures were treated (24 h) with increasing concentrations (10 -100 ng/ml) of halofuginone in serum-free medium. Aliquots of the conditioned medium were applied onto gelatin embedded SDS-polyacrylamide gel. The zymogram shown in Fig. 2a demonstrates that the gelatinolytic activity of the 72 kDa MMP-2 enzyme was markedly reduced by halofuginone. A noticeable decrease in MMP-2 activity was already revealed in cells treated with 10 ng/ml halofuginone and 80-90% inhibition of MMP-2 activity was exerted by 100 ng/ml halofuginone (Fig. 2a) . Activation of the proenzyme yielding a 68 kDa processed enzyme was even more readily affected by halofuginone (Fig. 2a) . Addition of halofuginone (100 -200 ng/ml) to the zymogram reaction buffer had no effect on MMP-2 activity (not shown), indicating that the drug does not exert a direct inhibitory effect on the MMP-2 enzyme itself.
Effect of halofuginone on BAEC invasion through Matrigel-coated filters
A necessary step in blood vessel formation is degradation of the subendothelial basement membrane by proteases. MMP-2 has previously been shown to play a central role in basement membrane degradation and endothelial cell invasion during the angiogenic process (reviewed in ref 2). We therefore tested the effect of halofuginone on BAEC invasion using the Matrigel invasion assay (30) . The presence of as little as 50 ng/ml halofuginone during the chemoinvasion assay resulted in a 60% inhibition of the ability of BAEC to invade through Matrigel-coated filters (Fig.  2b, filled bars) . (Fig. 2b, empty bars) , indicating no effect of halofuginone on cell viability and motility.
Inhibition of capillary-like tube formation by halofuginone
Vascular endothelial cells incubated on a Matrigel substratum align and form tubular structures (Fig.  3a) , mimicking certain steps in angiogenesis such as invasion, migration, and differentiation. Tube for- Figure 2 . Effect of halofuginone on endothelial cell MMP-2 activity and basement membrane invasion. a) MMP-2 activity. Subconfluent BAEC were incubated (12 h, 37°C) in the absence and presence of increasing concentrations (10 -100 ng/ml) of halofuginone in serum-free medium. Aliquots (20 -30 l) of the incubation media were normalized for equal protein concentration and applied for zymography on gelatin impregnated SDS/polyacrylamide gel electrophoresis, as described in Materials and Methods. b) Basement membrane invasion. Cultured BAEC were dissociated into a single cell suspension with EDTA, suspended (2ϫ10 5 cells/ml) in DMEM containing 0.1% bovine serum albumin, and incubated (6 h, 37°C) on top of Matrigel-coated filters (filled bars) in the absence and presence of increasing concentrations (10 -50 ng/ml) of halofuginone. The cells were also plated on filters coated with collagen type IV (empty bars) and incubated under the same conditions. The number of cells/field in the lower surface of the filter was determined as described in Materials and Methods. The results are the mean Ϯ sd of quadruplicate filters. mation by endothelial cells was shown to be dependent on MMP-2 activity (10). We therefore investigated the effect of halofuginone on the ability of BAEC to organize into capillary-like tubes on Matrigel. As shown in Fig. 3 , halofuginone inhibited the formation of tubular networks on Matrigel in a dose-dependent manner. A remarkable inhibition of tube formation was observed in the presence of 25 ng/ml halofuginone (Fig. 3b) and complete inhibition was obtained at 50 ng/ml halofuginone (Fig.  3c) . At the latter concentration, most of the cells appeared as unorganized cell aggregates (Fig. 3c) . Similar studies performed with human umbilical vein endothelial cells yielded the same pattern of inhibition (not shown).
Halofuginone inhibits endothelial cell sprouting in rat aortic rings
We tested the ability of halofuginone to inhibit microvessel formation in vitro, using rat aortic rings embedded in small intestinal submucosa gel (31) (32) (33) . SIS gel represents a physiological ECM that has been derived from porcine intestine while preserving its natural composition and architecture (31) . Due to these features, SIS gel enables several cell types, including endothelial cells, to maintain in culture their in vivo phenotype and 3-dimensional organization (32, 33) . In our experiments, branching microvessels forming a capillary network of tubes and loops were developed, starting on day 7-9, at the periphery of untreated aortic rings embedded in SIS gel, reaching a maximal degree of sprouting on days 12-14 (Fig. 4a) . In contrast, microvessel formation was almost completely inhibited in the presence of 60 ng/ml halofuginone. Under those conditions, single cells migrated out of the aortic ring, but failed to align into microvessel tubes (Fig. 4b) . Similar results were obtained with aortic explants embedded in collagen type I gel, commonly used in previous studies (35) . A quantitative analysis of the number of out-growing microvessels revealed a 50% inhibition of vascular tube formation at 25 ng/ml halofuginone and complete inhibition at 100 ng/ml halofuginone.
Effect of halofuginone on ECM deposition by cultured vascular endothelial cells
The last stage of angiogenesis is characterized by deposition of new basement membrane (17, 20) . Deposition of basement membrane-like ECM by cultured vascular and corneal endothelial cells has previously been demonstrated (36) . It was also found that the level of incorporated sulfate is a reliable measure of the amount of ECM deposited by these cells (25, 27) . To assess the effect of halofuginone on BM deposition, labeled sulfate (Na 2 35 SO 4 ) and increasing concentrations of halofuginone were added to confluent BAEC 24 and 96 h after seeding. On day 9, the cell layer was dissolved in order to expose the underlying ECM. The ECM was then digested with collagenase and the remaining material was trypsinized. The solubilized radioactivity was counted in a ␤-scintillation counter to evaluate the effect of halofuginone on the amount of collagenase digestible and nondigestible ECM constituents. As shown in Fig. 5 , deposition of ECM was inhibited by 80 -85% in the presence of 50 ng/ml halofuginone. This observation was supported by a microscopic examination of the denuded culture dishes, revealing a very thin or no ECM produced in the presence of halofuginone.
Anti-angiogenic activity of halofuginone in vivo
A murine corneal angiogenesis model was applied to evaluate the inhibitory effect of halofuginone in vivo. The angiogenic stimulant bFGF was applied into a corneal micropocket in a slow release polymer, as described in Materials and Methods, and halofuginone was administered either in the food (5 mg/kg) or i.p. (2 g/mouse/day) for 7 consecutive days. Control mice received a regular diet. On postoperative days 3 and 7, corneas were examined by slit lamp microscopy to determine the neovascular response and photographed. As demonstrated in Fig. 6 , neovascularization from the corneal limbus to the pellet occurred in the eyes of control mice (Fig. 6a, left) . A remarkable inhibition of the neovascular response to the pellet was observed in mice receiving oral halofuginone (Fig. 6a, middle and right) . On postoperative day 7, the average area of neovascularization in the control group was 1.75 Ϯ 0.27 mm 2 , as compared to 0.65 Ϯ 0.23 and 0.63 Ϯ 0.19 mm 2 in mice that received halofuginone in the food or by i.p. injections, respectively (Fig. 6b) .
DISCUSSION
Halofuginone is a nontoxic low molecular weight alkaloid compound (MWϭ495) that is used worldwide as an anti-parasitic drug in commercial poultry production (21) . Independent of this effect, halofuginone was found to be a specific inhibitor of collagen type ␣1(I) gene expression. Halofuginone was shown to inhibit collagen synthesis and ECM deposition in a variety of cell types (21, (23) (24) (25) (26) (27) , resulting in amelioration of a number of fibrotic disorders (24 -26) . Halofuginone Figure 5 . Effect of halofuginone on ECM deposition by BAEC. BAEC were seeded at a confluent cell density (5ϫ10 5 cells/16 mm well of a 24-well plate). One and three days after seeding, increasing concentrations of halofuginone (10 -200 ng/ml) were added together with Na 2 35 SO 4 (40 Ci/ml). Control cells were maintained in the absence of halofuginone. On day 9, the cell layer was solubilized to expose the underlying ECM as described in Materials and Methods. The ECM was washed with PBS (ϫ3), subjected to sequential digestion with collagenase and trypsin to determine the amount of sulfate incorporated into the ECM and released by collagenase (collagenase digestible proteins) (filled bars) or trypsin (noncollagenase digestible proteins) (empty bars). The results are the mean Ϯ sd of triplicate cultures. also effectively inhibits MMP-2 gene expression, and in combination with its other activities, exerts profound antitumor and anti-metastatic effects in various experimental models (22, 37, 38) . Decrease in vascular density and neovascularization in primary tumor tissue was reported after a systemic administration of halofuginone, indicating a possible anti-angiogenic activity of the drug (37, 38) .
In the present study, we demonstrate that halofuginone is a potent anti-angiogenic agent, affecting the main molecular and cellular events associated with the multistep angiogenic process. First, we tested the effects of halofuginone on the initial stages of angiogenesis, involving local proliferation of endothelial cells, degradation of the underlying basement membrane, and endothelial cell invasion into the underlying substratum. A 40 -60% decrease in endothelial cell proliferation was obtained in the presence of 100 -200 ng/ml halofuginone. The inhibitory effect of halofuginone on MMP-2 expression by endothelial cells, their invasion through reconstituted BM (Matrigel) and capillary-like tube formation was more pronounced, reaching almost complete inhibition at 50 -100 ng/ml. These findings are consistent with an inhibitory effect of halofuginone on MMP-2 promoter activity (22) . It has previously been shown that sprouting angiogenesis is clearly associated with enzymatic degradation of the subendothelial BM by MMP-2 secreted by endothelial cells (reviewed in ref 2). Treatment of endothelial cells with exogenous MMP-2 was reported to induce a dose-dependent morphological change consistent with an angiogenic response (i.e., capillary-like tube formation) (10) . Inhibition of enzymatic degradation of collagen type IV resulted in suppression of experimental tumorassociated angiogenesis (39, 40) . The significance of MMP-2 in angiogenesis was further emphasized by showing a marked inhibition of tumor-induced angiogenesis and tumor progression in MMP-2 deficient mice (11) . It is conceivable, therefore, that the observed suppression by halofuginone of both the invasive ability of endothelial cells and their differentiation into tubular structures on Matrigel is primarily due to the inhibition of MMP-2 expression.
Furthermore, inhibition of collagen type ␣1(I) gene expression by halofuginone may also play an Figure 6 . Inhibition of angiogenesis by systemic halofuginone. A sucralfate and Hydron pellet containing 80 -100 ng bFGF was implanted into a corneal micropocket created in C57BL/6 mice (one pellet per eye). On postoperative days 3 and 7, corneas were examined by slit lamp biomicroscopy and photographed. a) Neovascularization from the corneal limbus to the pellet was noted in the eyes of control mice (left). In contrast, a marked inhibition of angiogenesis was seen already on day 3 (middle) and an almost complete inhibition was observed on day 7 (right) in mice receiving halofuginone in the food (5 mg/kg diet). Original magnification ϫ10. b) Line graph showing a profound decrease in the area of neovascularization after systemic administration of halofuginone. Halofuginone was administered either in the food (5 mg/kg diet) (f) or by i.p. injections (2 g/ mouse, once a day) (F). Control mice received regular diet without halofuginone and i.p. injections of saline (Ⅺ). The area (mm 2 ) of vascularized zone was calculated as described in Materials and Methods. The results are the mean Ϯ sd, n ϭ 6. important role in the anti-angiogenic activity of the compound. The role of collagen type I in angiogenesis was emphasized in numerous studies. Type I collagen is believed to aid endothelial cell migration during sprouting angiogenesis and their proper assembly into newly formed capillaries (14, 15) . In vitro studies suggest that expression of type I collagen is initiated when endothelial cells undergo angiogenic sprouting (14) . Experimentally induced angiogenesis on the chicken chorioallantoic membrane (CAM) is associated with the deposition of large amounts of collagen (41) . Moreover, transcriptional activation of the collagen ␣1(I) gene was observed in endothelial cells undergoing angiogenesis in vitro (15) . It was also reported that when bovine aortic endothelial cells were exposed to angiogenic stimuli, collagen type I synthesis was up-regulated 4.5-fold (41) . Type I collagen fibrils were found to induce formation of capillary-like tubes by endothelial cells in vitro (16) . Electron microscopy revealed that the lumen of the tubes consisted of collagen fibrils, with the surrounding cells having typical endothelial junctional complexes (16) . Histological examination of normal, tumor, and experimentally induced angiogenesis demonstrated that collagen type I is localized within endothelial cords and tubes (42) . On the other hand, metabolic inhibition of collagen type I synthesis inhibits capillary formation on the CAM (43) . Endothelial cell migration from aortic explants embedded within collagen gels is inhibited when maintained in the presence of the proline analog cishydroxyproline, once again indicating the need for normal collagen synthesis (44). In light of the above data, it seems likely that collagen ␣1(I) suppression by halofuginone is responsible, at least in part, for abrogation of capillary tube formation on Matrigel and in the rat aortic ring assay, as reported in this study.
Basement membrane deposition by endothelial cells during the final phase of angiogenesis is the hallmark of blood vessel maturation (17, 20) . We demonstrated here that low concentrations (ϳ50 ng/ml) of halofuginone almost completely inhibited the deposition of BM-like ECM by vascular endothelial cells. It should be noted that the inhibitory effect of halofuginone on MMP-2 expression, as well as invasiveness, tube formation, and ECM deposition by endothelial cells, was not due to its antiproliferative activity. Although endothelial cell proliferation was inhibited (ϳ60 -70%) by halofuginone at concentrations as high as 200 -400 ng/ml halofuginone, all the other anti-angiogenic effects investigated in this study were exerted at 25-50 ng/ml of the compound. Thus, the potent anti-angiogenic activity of halofuginone both in vitro (Matrigel tube formation and aortic ring assays) and in vivo (corneal micropocket model) should be attributed primarily to the combined action of the compound on MMP-2 and collagen ␣1(I) gene expression and ECM deposition rather than to a direct inhibition of endothelial cell proliferation.
The diverse nature of angiogenesis and the range of its molecular and cellular mechanisms make it unlikely that inhibition of any single target in this process will abrogate neovascularization. Most of the proposed or clinically tested anti-angiogenic drugs are directed against a particular stage of the angiogenic cascade (i.e., factors promoting degradation of the subendothelial BM, endothelial cell proliferation, migration, interaction with ECM components, cell survival) (reviewed in ref 8). Our present results indicate that, in fact, halofuginone interferes with several sequential events during new blood vessel formation. The anti-angiogenic activity of halofuginone was best demonstrated in the mouse corneal micropocket model in which neovascularization was induced by bFGF and halofuginone was administered systemically, either in the diet or by i.p. injections. The oral bioavailability, lack of toxic effects, and long-term safe use in farm animals make halofuginone a promising candidate for further evaluation in cancer therapy and treatment of other angiogenesis related pathologies such as rheumatoid arthritis, psoriasis, and diabetic retinopathy.
